• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正常受试者以及接受血液透析或腹膜透析的肾衰竭患者静脉注射头孢曲松后的药代动力学情况。

Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.

作者信息

Ti T Y, Fortin L, Kreeft J H, East D S, Ogilvie R I, Somerville P J

出版信息

Antimicrob Agents Chemother. 1984 Jan;25(1):83-7. doi: 10.1128/AAC.25.1.83.

DOI:10.1128/AAC.25.1.83
PMID:6322683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC185440/
Abstract

The kinetic disposition of a single intravenous dose of ceftriaxone (250 to 665 mg) was studied in six normal subjects and nine patients with renal insufficiency and normal hepatic function. In normal subjects, ceftriaxone was eliminated with a t1/2 beta of 5.2 h (range, 4.1 to 5.8). The total body clearance (Qb) was 13.5 ml/kg per h (range, 8.4 to 23.3), and renal clearance was 8.3 ml/kg per h (range, 5.8 to 13.3). In patients with severe renal insufficiency requiring peritoneal or hemodialysis, the mean t1/2 beta was prolonged to 13.4 h (range, 7.7 to 15.8) and the mean Qb was reduced to 6.9 ml/kg per h (range, 3.4 to 12.8). The apparent volumes of distribution (Vc and Vss) were not different from those determined in normal subjects. Peritoneal dialysis did not remove ceftriaxone. The dialysate of three patients on continuous peritoneal dialysis did not contain any measureable ceftriaxone, and the kinetic disposition in these patients was similar to the hemodialysis patients between their dialysis treatment. During a 4-h hemodialysis session, the total body clearance of ceftriaxone was reduced, perhaps secondary to a decrease in hepatic blood flow induced by the hemodialysis procedure. After a 12- or 24-h dose regimen, predicted trough concentrations of ceftriaxone in plasma at steady state derived from kinetic data generated from the study and assuming linear pharmacokinetic behavior were well above the minimum inhibitory concentrations of most sensitive bacteria, suggesting the feasibility of a once-a-day dosage regimen especially for patients with severe renal insufficiency.

摘要

在6名正常受试者和9名肾功能不全但肝功能正常的患者中,研究了单次静脉注射头孢曲松(250至665毫克)后的动力学处置情况。在正常受试者中,头孢曲松的消除半衰期(t1/2β)为5.2小时(范围为4.1至5.8小时)。总体清除率(Qb)为每小时13.5毫升/千克(范围为8.4至23.3),肾清除率为每小时8.3毫升/千克(范围为5.8至13.3)。在需要腹膜透析或血液透析的严重肾功能不全患者中,平均t1/2β延长至13.4小时(范围为7.7至15.8小时),平均Qb降至每小时6.9毫升/千克(范围为3.4至12.8)。表观分布容积(Vc和Vss)与正常受试者中测定的值无差异。腹膜透析不能清除头孢曲松。三名接受持续腹膜透析患者的透析液中未检测到任何可测量的头孢曲松,这些患者的动力学处置情况与血液透析患者在透析治疗期间的情况相似。在4小时的血液透析过程中,头孢曲松的总体清除率降低,这可能是由于血液透析过程导致肝血流量减少所致。在12或24小时给药方案后,根据该研究生成的动力学数据并假设线性药代动力学行为预测的稳态时血浆中头孢曲松的谷浓度远高于大多数敏感细菌的最低抑菌浓度,这表明每日一次给药方案对于严重肾功能不全患者尤其可行。

相似文献

1
Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.正常受试者以及接受血液透析或腹膜透析的肾衰竭患者静脉注射头孢曲松后的药代动力学情况。
Antimicrob Agents Chemother. 1984 Jan;25(1):83-7. doi: 10.1128/AAC.25.1.83.
2
Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.
Eur J Clin Pharmacol. 1986;31(4):479-83. doi: 10.1007/BF00613528.
3
Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.不同程度肾功能损害患者的头孢曲松药代动力学。
Antimicrob Agents Chemother. 1984 Apr;25(4):438-42. doi: 10.1128/AAC.25.4.438.
4
Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis.肾衰竭患者及接受血液透析患者中头孢曲松的药代动力学。
Antimicrob Agents Chemother. 1983 Oct;24(4):529-32. doi: 10.1128/AAC.24.4.529.
5
Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
Clin Pharmacol Ther. 1985 Sep;38(3):285-9. doi: 10.1038/clpt.1985.172.
6
Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.西多福韦在肾功能不全及持续性非卧床腹膜透析或高通量血液透析患者中的药代动力学。
Clin Pharmacol Ther. 1999 Jan;65(1):21-8. doi: 10.1016/S0009-9236(99)70118-9.
7
Pharmacokinetics of ceftriaxone in subjects with renal insufficiency.头孢曲松在肾功能不全患者中的药代动力学。
Clin Pharm. 1985 Mar-Apr;4(2):177-81.
8
Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.肾功能不全患者及血液透析期间头孢噻肟和去乙酰头孢噻肟的消除动力学
Chemotherapy. 1983;29(1):4-12. doi: 10.1159/000238166.
9
Cefotaxime disposition pharmacokinetics during peritoneal dialysis.头孢噻肟在腹膜透析期间的处置药代动力学。
Pharmacol Toxicol. 1987 May;60(5):321-4. doi: 10.1111/j.1600-0773.1987.tb01518.x.
10
Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.肾功能受损、血液透析及腹膜透析对美洛西林药代动力学的影响。
Antimicrob Agents Chemother. 1980 Jul;18(1):81-7. doi: 10.1128/AAC.18.1.81.

引用本文的文献

1
Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.基于生理的头孢曲松在健康人群和慢性肾病患者中单剂量和多剂量给药方案的药代动力学建模:一种模型指导精准给药的工具。
Front Pharmacol. 2023 Jul 20;14:1200828. doi: 10.3389/fphar.2023.1200828. eCollection 2023.
2
Ceftriaxone-induced acute encephalopathy in a peritoneal dialysis patient.一名腹膜透析患者发生头孢曲松所致的急性脑病。
Case Rep Nephrol. 2014;2014:108185. doi: 10.1155/2014/108185. Epub 2014 Dec 7.
3
Daily variations in ceftriaxone pharmacokinetics in rats.大鼠体内头孢曲松药代动力学的每日变化
Antimicrob Agents Chemother. 2003 Feb;47(2):809-12. doi: 10.1128/AAC.47.2.809-812.2003.
4
Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.头孢曲松:其在社区获得性感染和医院感染管理中应用的最新情况
Drugs. 2002;62(7):1041-89. doi: 10.2165/00003495-200262070-00005.
5
Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.胃肠外头孢菌素类药物的药理学特性:门诊使用的理论依据。
Drugs. 2000;59 Suppl 3:9-18; discussion 47-9. doi: 10.2165/00003495-200059003-00002.
6
Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.头孢曲松。对其抗菌活性、药理特性及治疗用途的综述。
Drugs. 1984 Jun;27(6):469-527. doi: 10.2165/00003495-198427060-00001.
7
Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.接受腹膜透析患者的药物治疗。临床药代动力学考量
Clin Pharmacokinet. 1985 Sep-Oct;10(5):404-25. doi: 10.2165/00003088-198510050-00003.
8
Clinical pharmacokinetics of the third generation cephalosporins.第三代头孢菌素的临床药代动力学
Clin Pharmacokinet. 1985 Mar-Apr;10(2):101-43. doi: 10.2165/00003088-198510020-00001.
9
Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.
Eur J Clin Pharmacol. 1986;31(4):479-83. doi: 10.1007/BF00613528.
10
Ceftriaxone pharmacokinetics during peritoneal dialysis.头孢曲松在腹膜透析期间的药代动力学。
Eur J Clin Pharmacol. 1986;30(3):303-7. doi: 10.1007/BF00541533.

本文引用的文献

1
Multiple intravenous dose pharmacokinetics of ceftriaxone in man.头孢曲松在人体中的多次静脉给药药代动力学
Chemotherapy. 1981;27 Suppl 1:47-56. doi: 10.1159/000238029.
2
Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion.通过腹膜透析、血液透析和活性炭血液灌流清除西咪替丁。
Ther Drug Monit. 1980;2(3):273-81. doi: 10.1097/00007691-198007000-00011.
3
Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.浓度依赖性血浆蛋白结合对头孢曲松动力学的影响。
Clin Pharmacol Ther. 1981 May;29(5):650-7. doi: 10.1038/clpt.1981.90.
4
Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.头孢曲松(Ro 13 - 9904)的抗菌活性,一种对β-内酰胺酶稳定的头孢菌素。
Antimicrob Agents Chemother. 1981 Mar;19(3):414-23. doi: 10.1128/AAC.19.3.414.
5
Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.正常成年人静脉注射头孢曲松的药代动力学特征。
Antimicrob Agents Chemother. 1982 Nov;22(5):816-23. doi: 10.1128/AAC.22.5.816.
6
Efficacy of a twelve-hourly ceftriaxone regimen in the treatment of serious bacterial infections.每12小时一次头孢曲松治疗方案对严重细菌感染的疗效。
Antimicrob Agents Chemother. 1982 Jul;22(1):103-7. doi: 10.1128/AAC.22.1.103.
7
Efficacy of ceftriaxone in serious bacterial infections.头孢曲松在严重细菌感染中的疗效。
Antimicrob Agents Chemother. 1982 Mar;21(3):402-6. doi: 10.1128/AAC.21.3.402.
8
A study of the relationship between dose and pharmacokinetics of ceftriaxone.头孢曲松剂量与药代动力学关系的研究。
J Antimicrob Chemother. 1982 Jan;9(1):57-62. doi: 10.1093/jac/9.1.57.
9
Pharmacokinetics of ceftriaxone in humans.头孢曲松在人体内的药代动力学。
Antimicrob Agents Chemother. 1981 Nov;20(5):634-41. doi: 10.1128/AAC.20.5.634.
10
A pharmacokinetic and tolerance study of Ro13-9904, a new cephalosporin antibiotic.新型头孢菌素抗生素Ro13-9904的药代动力学及耐受性研究
Br J Clin Pharmacol. 1981 Aug;12(2):111-5. doi: 10.1111/j.1365-2125.1981.tb01188.x.